The IVI Board of Directors is comprised of members representing various classes of stakeholders, including research and academia, providers, patients, payers, pharmaceutical and medical device companies, as well as other companies in the healthcare industry. The Board is responsible for overseeing the financial and strategic direction of the organization and provides advice and leadership support to IVI’s Executive Director and staff team to execute its work.
Alan Balch, PhD (Secretary)
Patient Advocate Foundation
Alan Balch, PhD
Dr. Balch has served on the Executive Board of PAF and NPAF since 2007. He also serves on numerous advisory boards and committees.
He earned his PhD in environmental studies with a concentration in political economy from the University of California, Santa Cruz; master’s degree in environmental sciences in 1997 from the University of Texas in San Antonio; and bachelor’s degree (cum laude) in biology in 1994 from Trinity University in San Antonio.
Donna Cryer, JD
Global Liver Institute
Donna Cryer, JD
Mrs. Cryer serves on the Executive Committees for the Clinical Trials Transformation Initiative (CTTI) and the People-Centered Research Foundation, the Board of Trustees of Sibley Memorial Hospital/Johns Hopkins Medicine and the Executive Advisory Board for Tivity Health (NASDAQ: TVTY).
Mrs. Cryer previous health data experience includes being appointed by the U.S. GAO to serve as the patient and consumer representative on the Health Information Technology Policy Committee, the federal advisory body to the National Coordinator for HIT, after serving on the Consumer Engagement and Privacy/Security Workgroups and as a member of Stakeholder Advisory Group to the NIH Learning Health System Research Collaboratory. She is a frequent speaker on patient engagement with health information technology at meetings of BIO, PhRMA, AHIP, National Quality Forum, mHealth Summit, Digital Health Summit, and the National Academies of Medicine.
Mrs. Cryer received an undergraduate degree from Harvard/Radcliffe Colleges and a Juris Doctorate from the Georgetown University Law Center.
Greg Daniel, PhD
Greg Daniel, PhD
Greg has 20 years of distinguished experience in healthcare policy and research. As a recognized health policy leader, Greg spent almost a decade leading pharmaceutical and medical device policy in the areas of value-based healthcare and payment, real-world evidence development, and FDA regulatory science. Prior to joining Edwards, Greg was the Deputy Center Director at the Duke-Margolis Center for Health Policy and Clinical Professor at Duke’s Fuqua School of Business where he directed the Washington, DC office and led the Center’s biomedical innovation policy portfolio. Prior to that he was a Fellow and Managing Director in the Center for Health Policy at the Brookings Institution. In addition, he was the Vice President, Government and Academic Research, at HealthCore Inc., an Anthem Company, where he lead large observational research studies focused in health economics and outcomes research, real world evidence, and safety and epidemiology that leveraged administrative claims, electronic health record, and other real-world data sources.
Greg is currently the Editor-In-Chief of Therapeutic Innovation & Regulatory Science scientific journal has recently joined the Board of Directors for the Innovation and Value Initiative (IVI). Greg holds a PhD in Pharmaceutical Economics, Policy, and Outcomes from the University of Arizona, and an MPH in Biostatistics, MS in Pharmaceutical Administration and a BS in Pharmacy, all from The Ohio State University.
Dan Durham, MPP (Treasurer)
Biotechnology Innovation Organization
Daniel Durham, MPP
Patty Fritz, MA
Patty Fritz, MA
In her role, Patty finds opportunities to better understand the unique needs of patients, so we can continue delivering value. She is a champion of innovative projects to spotlight the importance of access and care for people living with severe diseases.
Patty has made a significant impact in different leadership roles including regulatory affairs, operational excellence, government affairs, health policy, and UCBCares®. Patty led the regulatory efforts for UCB’s first product filing in the US – Keppra® (levetiracetam) – and oversaw the FDA approval process for many of UCB’s other products.
Prior to joining UCB, Patty held positions with the government and industry in regulatory affairs, clinical development, and research.
Patty has also championed and was a driving force behind the establishment of UCB’s Women in Leadership initiative. She was recently recognized by PharmaVOICE magazine as one of the 100 most influential and inspirational leaders in the life sciences industry in 2019.
Outside of UCB, Patty serves as chair of the board of directors for Georgia Bio and as a member of The Carter Center Board of Councilors. She splits her time between Washington, D.C. and Atlanta, where she enjoys spending time with her family.
Patty holds a master’s degree in health care policy and administration from Mercer University (Atlanta, Ga.) and a Bachelor of Science degree in management and technology from the University of Maryland (Laurel, Md.). Patty is also a graduate of Summers County School of Nursing (Hinton, W.Va.).
Andrea Maresca, PhD
Andrea Maresca, MPH
Andrea Maresca brings extensive federal, state and non-profit health policy experience, particularly in relation to the Medicaid program. She possesses a unique perspective on the intersection of federal and state health care policy and programs. During her nearly two decades in the field, she has earned a reputation as an insightful analyst and strategic thinker with the ability to develop, communicate, and advance bipartisan policy solutions.
Prior to Thorn Run Partners, Andrea served at the Centers for Medicare and Medicaid Services (CMS)—first in the Office of Legislation, then as Special Assistant and Advisor to the Deputy Administrator. In this role, she provided strategic counsel and helped to advance several of the agency’s top priorities early in the Trump Administration.
Before joining CMS, Andrea spent a combined ten years at the National Association of Medicaid Directors (NAMD) and National Governors Association (NGA). As the Director of Federal Policy and Strategy at NAMD, Andrea solidified the organization as the go-to source for analysis and perspectives on critical issues facing state Medicaid programs during implementation of the Affordable Care Act. As the Legislative Director for Health Policy at NGA, she helped to forge bipartisan positions and support governors on major federal legislation and regulations, including the Affordable Care Act, the Recovery Act of 2009, and reauthorization of the Children’s Health Insurance Program in 2007.
Andrea has also held positions with the Association for Community Affiliated Plans and the National Association of Community Health Centers, and as a speechwriter and legislative staffer for Congresswoman Rosa DeLauro. She first came to Washington, D.C., as a Mickey Leland Hunger Fellow.
Ms. Maresca earned her Master’s in Public Health from George Washington University and her bachelor’s degree from Villanova University.
Sam Nussbaum, MD (President)
Samuel Nussbaum, MD
Dr. Nussbaum serves as a Strategic Consultant to EBG Advisors, consulting arm for Epstein Becker and Green, where he advises life science companies, health care systems, and provider organizations. He also serves as a Senior Advisor to Sandbox Industries, a health care venture fund.
From 2000 until 2016, Dr. Nussbaum served as Executive Vice President, Clinical Health Policy, and Chief Medical Officer for Anthem. In that role, he was the key spokesperson and policy advocate and oversaw clinical strategy and corporate medical and pharmacy policy.
During his tenure at Anthem, he was responsible for over $100B in annual health care expenditures through business units focused on care management, health improvement, and provider network contracting. Dr. Nussbaum was instrumental in developing contracting approaches that link hospital reimbursement to quality, safety and clinical performance; and patient-centered medical homes, assessing their impact on the quality and cost effectiveness of care. Under his leadership, HealthCore has built partnerships with Federal agencies and academic institutions to advance drug safety, comparative effectiveness and outcomes research.
Dr. Nussbaum currently serves on the Board of Directors of NEHI, America’s Agenda and PhyMed. He is a member of the Scientific Advisory Board of Medidata, the Healthcare Advisory Board of KPMG, the HHS Health Care Payment Learning and Action Network (LAN) Guiding Committee, Chairs the Innovation and Value Initiative (IVI) Board of Advisors, and participates in National Academy of Medicine initiatives.
National Alliance of Healthcare Purchaser Coalitions
Prior to joining the National Alliance, Mike was a Principal at PricewaterhouseCoopers (PwC) for 20 years working with employers and other stakeholders and served as an executive with diverse roles with Prudential Healthcare for over 17 years. Mike is a Fellow of the Society of Actuaries, serving on the Health Practice Council, and chair of the Medicare Sub-Committee of the American Academy of Actuaries (AAA). He is also widely recognized as a leading national advocate for mental health and wellbeing and previously served as President of the New York City chapter of the National Alliance for Mental Illness (NAMI). Mike also served as an active member of the board of the Northeast Business Group on Health for 11 years.
Neil Weissman, MD
Neil Weissman, MD
Neil J. Weissman, MD, FACC, FASE, is the Chief Scientific Officer for MedStar Health and President of MedStar Health Research Institute. Dr. Weissman is a professor of medicine at Georgetown University School of Medicine and an internationally recognized cardiologist with expertise in echocardiography and clinical trials.
As chief scientific officer, he provides leadership for the development and implementation of specific scientific priorities, with a commitment to further advancing MedStar Health as an academic healthcare system. As president of the Research Institute, he is responsible for the overall strategic and operational direction of the research arm of MedStar Health.
Dr. Weissman’s research interests include the use of cardiovascular ultrasound imaging in clinical trials and the development of artificial intelligent applications for imaging. He has served as principal investigator for numerous national and international multi-center trials served on several national organizations and editorial boards and written hundreds of original reports published in high profile peer-reviewed journals. He is frequently invited to serve as an expert on U.S. Food and Drug Administration advisory panels and National Institutes of Health commissions and held many national leadership positions including past president of the American Society of Echocardiography and past chair of the American College of Cardiology’s Imaging Council.
Dr. Weissman received his medical degree from Cornell University Medical College in New York. He completed his internship, residency and chief residency in Internal Medicine at New York Hospital. He followed his residency training with a clinical and research fellowship in Cardiology and a fellowship in Cardiac Ultrasound at Massachusetts General Hospital in Boston.